PBF-509 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2

6. パーキンソン病

---

臨床試験数 : 2,298 /  薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02111330 (ClinicalTrials.gov)	March 2014	20/3/2014	Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers	Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers	Parkinson Disease	Drug: PBF-509;Drug: Placebo	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Palo Biofarma, S.L	Completed	18 Years	45 Years	Both	16	Phase 1	Spain
2	NCT01691924 (ClinicalTrials.gov)	October 2012	13/9/2012	Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers	Randomized, Double Blind, Placebo Controlled First In-human Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy Volunteers	Parkinson Disease	Drug: PBF-509;Drug: Placebo	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Palo Biofarma, S.L	Completed	18 Years	45 Years	Male	56	Phase 1	Spain